All news

BioMarin flags USD 283 million R&D charge

Alpha Vantage · AD HOC NEWS · · AI-summarised by FinFlash

BioMarin Pharmaceutical disclosed a USD 283 million in-process research and development expense for Q3 2026, which will cut both GAAP and non-GAAP diluted earnings per share by USD 1.50. The charge came alongside Q2 2026 revenue of USD 989.70 million, up 20.00 percent year over year, and raised full-year 2026 revenue and EPS guidance. BioMarin shares fell 1.83 percent on Tradegate.

Read original source

BMRN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.